![]() ![]() The use of EXCOR ® VAD for adults, RVAD-support, EXCOR ® venous cannulas with grafts, Excor mobile and EXCOR ® Active is not FDA-approved and not available for commercial use in the US.Accurate cardiac motion estimation from medical images such as ultrasound is important for clinical evaluation. 030 8187 The access to some or all shown products may be restricted by country-specific regulatory approvals. Users can also access round-the-clock medical and technical support. With the EXCOR ® Adult and the EXCOR ® Pediatric, Berlin Heart is the only company in the world able to provide support to patients of every age and size, from infants to adults.īerlin Heart’s systems provide left ventricular, right ventricular, or biventricular support (both sides) hospitals around the world use the system for short-, medium-, and long-term circulatory support, providing patients with a life-saving treatment option. “Conducting this study is another example of how Berlin Heart gives patients, parents and clinical partners a voice to target patient-centered innovations.”įor more information about the “E-Motion”- study, please visit:īerlin Heart GmbH develops, manufactures, and markets innovative ventricular assist devices (VADs) for mechanical circulatory support. Menon, Managing Director of Berlin Heart. Oliver Miera, Pediatric Cardiologist and Coordinating Investigator of the “E-Motion” study describes the intention: “The “E-Motion” study will provide valuable information of how we can offer children with end-stage heart failure more mobility and autonomy in their daily lives in the hospital environment.”Ĭlinical Research helps Berlin Heart to pursue a very clear vision: “With our life-saving therapies, we want to improve the quality of life of children with heart failure,” explains Dr. The first three study patients are treated at the German Heart Institute in Berlin, Germany. The impact on the lives of the patients and their families will be assessed with Quality of Life questionnaires. Patients or their parents will keep a mobility diary to gain information on how the EXCOR ® Active supports the mobilization of the children. On the seventh day the children get switched to the mobile driving unit EXCOR ® Active and will be observed for another 45 days. During the first week, information is collected, while the pediatric patients are still connected to the stationary driving unit IKUS. Every patient is observed for a 52-day time frame. We plan to conduct the trial at ten study centers in five countries.”Īs soon as the patient is able to get mobilized after implantation of the EXCOR ® VAD, the patient can be included into the study. “All these children suffer from advanced heart failure and are waiting for a heart transplantation. Thomas Schöndorf, Manager Clinical Research at Berlin Heart. “Within the prospective, clinical “E-Motion” study, we will observe twenty pediatric patients supported by the EXCOR ® VAD,” outlines PD Dr. ![]() This observational, international, multi-center study investigates the improved mobility, patient outcome and the impact of the mobile driving concept EXCOR ® Active on quality of life, compared to the stationary driving unit IKUS.īerlin, April 2021: EXCOR ® Active is the innovative new driving unit that gives children, waiting for a donor heart more freedom to move, play and learn during their time on the EXCOR ® Ventricular Assist Device. Everyday life with the EXCOR ® Pediatric.How do ventricular assist devices work?. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |